HOME >> MEDICINE >> NEWS
GL701 (prasterone) significantly reduces lupus flares

Philadelphia, Pa. - Oct. 31, 2000 - The incidence of debilitating flares or exacerbations that systemic lupus erythematosus (SLE or lupus) patients experience, some resulting in hospitalization, significantly declined with the use of GL701, according to a Phase III placebo-controlled, double-blind multicenter study conducted in Taiwan and presented at the 64th Annual Scientific Meeting of the American College of Rheumatology in Philadelphia. The drug used in this study is similar to Genelabs Technologies, Inc. (Nasdaq:GNLB) formulation of its investigational drug GL701. The study reported here today was conducted by Genelabs Biotechnology Co., Ltd. of Taiwan, a licensee of Genelabs Technologies, Inc.

"GL701 significantly reduced the percent of patients with flares. Since flares can punctuate the remission periods that lupus patients experience, the potential for this investigational drug to increase the duration of remission and decrease the number of flares that require hospitalization is an important therapeutic advance," says Deh-Ming Chang, M.D., coauthor of the study and Professor and Director of Rheumatology/Immunology at the Tri-Service General Hospital, Taipei, Taiwan, R.O.C.

In the study, Chang and his colleagues compared GL701 to placebo among 119 Taiwanese women with lupus. Patients were evaluated in a randomized double-blind comparison of GL701, 200 mg or placebo daily for 24 weeks. Investigators evaluated efficacy based on change in Systemic Lupus Activity Measure (SLAM) and change in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), which measure disease activity; physician and patient visual analog scales (VAS), which measure quality of life parameters; and percent of patients with definite flares.

Study results show that 18 percent of patients receiving GL701 experienced flares, compared to 34 percent of patients on placebo, a 46 percent reduction, which was significant (p=0.04). Moreover, no GL701 pa
'"/>

Contact: Beth Kaplan
212-601-8443
Porter Novelli
30-Oct-2000


Page: 1 2 3

Related medicine news :

1. Moving admitted ER patients into inpatient beds faster could significantly increase hospital revenue
2. Gastrointestinal disorders are associated significantly with sleepless nights
3. Landmark survey reveals asthma in children remains significantly out of control in the United States
4. Data suggest ADDERALL XR significantly improved simulated driving in young adults with ADHD
5. Elderly cancer patients are significantly under-represented in cancer clinical trials
6. Generic anti-inflammatory causes significantly fewer GI complications than branded medications
7. Study shows weight-based REBETOL dosing in combination with PEG-INTRON significantly improves ...
8. Radiotherapy + cetuximab significantly improve disease control and survival in head and neck cancer
9. New data show SPIRIVA significantly reduces COPD exacerbations and related health resource burden
10. GSKS Requip(R) (ropinirole HCl) significantly reduces periodic leg movements in patients with RLS
11. Two landmark studies show Taxotere (R) significantly improves survival in men with prostate cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: prasterone significantly reduces lupus flares

(Date:3/4/2015)... New York (PRWEB) March 04, 2015 ... ) that allege the statin drug caused patients to ... the U.S. District Court, District of South Carolina. According ... be convened on March 26, 2015 at 10:00 a.m. ... directed to submit a Joint Status report to the ...
(Date:3/4/2015)... 04, 2015 FDA’s New Inspection Approach:, ... Webinar**, March 24, 2015 — 1:30 p.m. – 3:00 ... know within four hours of an inspection whether a ... on their “good” list, they’ll merely ask for reassurance ... is on the “bad” list, the manufacturer must get ...
(Date:3/4/2015)... 04, 2015 The ability of ... density assessment and help improve breast cancer risk ... accepted for presentation at the European Congress of ... abstracts - eight posters and 2 session presentations ... breast density and quantitative breast imaging software tools ...
(Date:3/4/2015)... March 04, 2015 With the growing influence ... lives of our teens and young adults, combined with the ... and confusing to try to keep up with what kids ... or trend is replaced on a daily basis. , The ... and the slang that is used to discreetly talk about ...
(Date:3/4/2015)... York (PRWEB) March 04, 2015 More ... the cardiovascular risks potentially associated with low testosterone treatments ... (FDA) announced that it will now require manufacturers to ... their risk for heart attacks and strokes. In a ... the agency also stated that it was requiring testosterone ...
Breaking Medicine News(10 mins):Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 2Health News:Lipitor Lawsuit News: Bernstein Liebhard LLP Comments on Scheduling of Status Conference in Federal Lipitor Litigation 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 2Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 3Health News:FDAnews Announces: FDA’s New Inspection Approach: What Your Inspector Knows in Four Hours Webinar, March 24, 2015 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 2Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 3Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 4Health News:Research Finds Use of Volpara Solutions’ Quantitative Breast Imaging Tools Help Reduce Subjectivity in Density Assessment and Improve Breast Cancer Risk Prediction 5Health News:Per Wickstrom Offers Guide to Parents for Keeping Youth Sober 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 2Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 3Health News:Testosterone Lawsuit Attorneys at Bernstein Liebhard LLP Comment on FDA Mandate For New Cardiovascular Warnings on Low T Therapy Drugs 4
(Date:3/4/2015)... , March 4, 2015  NxStage Medical, Inc. (Nasdaq: ... today announced that Jeffrey H. Burbank , Chief Executive ... in Miami, FL on Wednesday, March ... webcast of the event will be made available at ... About NxStage NxStage Medical, Inc. (Nasdaq: ...
(Date:3/4/2015)... AUSTIN, Texas , March 4, 2015 /PRNewswire/ ... Phase II pilot study in patients with moderate ... JAMA Dermatology. The open-label Phase II trial evaluated ... Human™ monoclonal antibody that targets interleukin-1 alpha (IL-1a). ... and inflammatory cells present in skin lesions. The ...
(Date:3/4/2015)...  Results of the recent study, Results From ... Intra-Operative Positive Margin Detection , were presented as part ... Annual Miami Breast Cancer Conference last week. ... , MD, FACS, Professor of Surgery at the Sackler ... analysis of MarginProbe,s efficiency and accuracy when used consecutively ...
Breaking Medicine Technology:NxStage to Present at the Barclays Capital Global Healthcare Conference 2XBiotech Announces Phase II Psoriasis Study Results in JAMA Dermatology 2New Study Shows Breast Re-excision Rates Significantly Reduced in 100 Consecutive Cases 2
Cached News: